155 related articles for article (PubMed ID: 36843255)
1. Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy.
Patnaik SK; Swaroop AK; Nagarjuna P; Nanjan MJ; Chandrasekar MJN
Curr Mol Pharmacol; 2024; 17(1):e240223214012. PubMed ID: 36843255
[TBL] [Abstract][Full Text] [Related]
2. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
[TBL] [Abstract][Full Text] [Related]
3. Virtual high throughput screening of natural peptides against ErbB1 and ErbB2 to identify potential inhibitors for cancer chemotherapy.
Patnaik SK; Ayyamperumal S; Jade D; Palathoti N; Akey KS; Jupudi S; Harrison MA; Ponnambalam S; Mj N; Mjn C
J Biomol Struct Dyn; 2023 Jun; ():1-24. PubMed ID: 37387589
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
5. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
6. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
8. ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma.
Liu S; Geng R; Lin E; Zhao P; Chen Y
Front Genet; 2021; 12():602160. PubMed ID: 33732282
[TBL] [Abstract][Full Text] [Related]
9. EGFR signaling in breast cancer: bad to the bone.
Foley J; Nickerson NK; Nam S; Allen KT; Gilmore JL; Nephew KP; Riese DJ
Semin Cell Dev Biol; 2010 Dec; 21(9):951-60. PubMed ID: 20813200
[TBL] [Abstract][Full Text] [Related]
10. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
11. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
Dhomen NS; Mariadason J; Tebbutt N; Scott AM
Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to HER family targeting antibodies.
Kruser TJ; Wheeler DL
Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
[TBL] [Abstract][Full Text] [Related]
14. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
15. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
16. Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.
Cheng W; Hu Y; Sheng R
Curr Med Chem; 2014; 21(38):4374-404. PubMed ID: 25245375
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D.
Yang L; Li Y; Bhattacharya A; Zhang Y
Oncotarget; 2016 Jul; 7(27):42340-42352. PubMed ID: 27286447
[TBL] [Abstract][Full Text] [Related]
18. Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations.
Ni J; Zhang L
Onco Targets Ther; 2021; 14():4087-4098. PubMed ID: 34262294
[TBL] [Abstract][Full Text] [Related]
19. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
